The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Extracellular barriers in respiratory gene therapy
Open accessAbstract
Respiratory gene therapy has been considered for the treatment of a broad range of pulmonary disorders. However, respiratory secretions form an important barrier towards the pulmonary delivery of therapeutic nucleic acids. In this review we will start with a brief description of the biophysical properties of respiratory mucus and alveolar fluid. This must allow the reader to gain insights into the mechanisms by which respiratory secretions may impede the gene transfer efficiency of nucleic acid containing nanoparticles (NANs). Subsequently, we will summarize the efforts that have been done to understand the barrier properties of respiratory mucus and alveolar fluid towards the respiratory delivery of therapeutic nucleic acids. Finally, new and current strategies that can overcome the inhibitory effects of respiratory secretions are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mucus clearance as a primary innate defense mechanism for mammalian airways
Knowles, M. R., & Boucher, R. C. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215217 · Cited by 1,054
Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus
Lai, S. K., O'Hanlon, D. E., Harrold, S., Man, S. T., Wang, Y.-Y., Cone, R., & Hanes, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608611104 · Cited by 1,050
Alveolar epithelial type II cell: defender of the alveolus revisited
Fehrenbach, H. (2001) · Respiratory Research · doi:10.1186/rr36 · Cited by 757 · cited 1×
“Indeed, inhaled pathogens can become opsonized by SP-A, SP-D, and immunoglobulins and subsequently eliminated via alveolar macrophages [45].”
BackgroundEfficient gene transfer to airway epithelium using recombinant Sendai virus
Yonemitsu, Y., Kitson, C., Ferrari, S., Farley, R., Griesenbach, U., Judd, D., Steel, R., Scheid, P., Zhu, J., Jeffery, P. K., et al. (2000) · Nature Biotechnology · doi:10.1038/79463 · Cited by 244
Cited by
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues
Lai, S. K., Wang, Y.-Y., & Hanes, J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.11.002 · Cited by 1,815
Supramolecular Amphiphiles Based on Host–Guest Molecular Recognition Motifs
Yu, G., Jie, K., & Huang, F. (2015) · Chemical Reviews · doi:10.1021/cr5005315 · Cited by 1,025
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
Self-citationMaterials engineering for immunomodulation
Hubbell, J. A., Thomas, S. N., & Swartz, M. A. (2009) · Nature · doi:10.1038/nature08604 · Cited by 561
Physicochemical properties of mucus and their impact on transmucosal drug delivery
Leal, J., Smyth, H. D. C., & Ghosh, D. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.09.018 · Cited by 560
Delivery strategies for sustained drug release in the lungs
Loira-Pastoriza, C., Todoroff, J., & Vanbever, R. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.017 · Cited by 393
Mucus Penetrating Nanoparticles: Biophysical Tool and Method of Drug and Gene Delivery
Ensign, L. M., Schneider, C., Suk, J. S., Cone, R., & Hanes, J. (2012) · Advanced Materials · doi:10.1002/adma.201201800 · Cited by 290
Ruge, C. A., Kirch, J., & Lehr, C.-M. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70072-9 · Cited by 280
Mucus as a barrier to lipophilic drugs
Sigurdsson, H. H., Kirch, J., & Lehr, C.-M. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.05.040 · Cited by 280
Mastorakos, P., da Silva, A. L., Chisholm, J., Song, E., Choi, W. K., Boyle, M. P., Morales, M. M., Hanes, J., & Suk, J. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502281112 · Cited by 210
Controlled pulmonary drug and gene delivery using polymeric nano-carriers
Beck-Broichsitter, M., Merkel, O. M., & Kissel, T. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.004 · Cited by 200
Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide
Qiu, Y., Man, R. C. H., Liao, Q., Kung, K. L. K., Chow, M. Y. T., & Lam, J. K. W. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.026 · Cited by 178
Nanodelivery in airway diseases: Challenges and therapeutic applications
Roy, I., & Vij, N. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.07.001 · Cited by 137
Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases
Sahu, I., Haque, A. K. M. A., Weidensee, B., Weinmann, P., & Kormann, M. S. D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.019 · Cited by 104
Suk, J. S., Boylan, N. J., Trehan, K., Tang, B. C., Schneider, C. S., Lin, J.-M. G., Boyle, M. P., Zeitlin, P. L., Lai, S. K., Cooper, M. J., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.160 · Cited by 94
Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases
Vij, N., Min, T., Bodas, M., Gorde, A., & Roy, I. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2016.06.008 · Cited by 85
Air-Liquid interface cultures to model drug delivery through the mucociliary epithelial barrier
Lee, R. E., Reidel, B., Nelson, M. R., Macdonald, J. K., Kesimer, M., & Randell, S. H. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114866 · Cited by 71
Therapeutic Prospects of mRNA-Based Gene Therapy for Glioblastoma
Tang, X., Zhang, S., Fu, R., Zhang, L., Huang, K., Peng, H., Dai, L., & Chen, Q. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01208 · Cited by 69
Intracranial delivery of synthetic mRNA to suppress glioblastoma
Peng, H., Guo, X., He, J., Duan, C., Yang, M., Zhang, X., Zhang, L., Fu, R., Wang, B., Wang, D., et al. (2022) · Molecular Therapy - Oncolytics · doi:10.1016/j.omto.2021.12.010 · Cited by 30
Metadata
- Authors
- Sanders, N., Rudolph, C., Braeckmans, K., De Smedt, S. C., & Demeester, J.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2009-02
- Volume
- 61
- Issue
- 2
- Pages
- 115-127
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2125445020
- Cited by
- 229
- References
- 4
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.